Clinical Effect Observation of Jianpishugan and Huoxuehuatan Formula on Liver Depression and Spleen Deficiency Induced Non-Alcoholic Steatohepatitis

OBJECTIVE To study the clinical effect of Jianpishugan and Huoxuehuatan formula on liver depression and spleen deficiency induced non-alcoholic steatohepatitis. METHODS 140 patients with liver depression and spleen deficiency induced non-alcoholic steatohepatitis admitted in our hospital from Oct. 2015 to Oct. 2016 were selected and randomly divided into the observation group and the control group according to the random number. Both groups were given exercise and diet therapy， and the control group was also treated with polyene phosphatidylcholine capsules. Based on the control group， the observation group was also treated with modified Jianpishugan and Huoxuehuatan Formula. RESULTS Symptom scores and the total scores of the clinical symptoms in two groups decreased significantly (P<0.01) after the treatment， but that in the observation group decreased more significantly (P<0.01). Total effective rate of overall efficacy in the observation group was 94.28% after the treatment， which was significantly higher than that in the control group (77.14%， P<0.01). Total effective rate of TCM syndrome in the observation group was 95.71% after the treatment， which was significantly higher than that in the control group (77.14%， P<0.01). ALT， AST and GGT levels in two groups decreased significantly (P<0.01) after the treatment， but that in the observation group decreased more significantly (P<0.01). Abdominal B ultrasound results in two groups improved significantly after the treatment(P<0.01)， but that in the observation group improved more significantly (P<0.01). During the treatment， patients in two groups did not complain of other discomforts， adverse reactions and toxic effects. CONCLUSION Jianpishugan and Huoxuehuatan Formula can noticeably improve the clinical symptoms and liver functions of patients with liver depression and spleen deficiency induced non-alcoholic steatohepatitis.